Clinical trials: Schizophrenic Disorders
Schizophrenia
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia
This study was conducted to evaluate the efficacy, safety, and tolerability of AVP-786, as compared with placebo, for the treatment of negative symptoms of schizophrenia.
- Trial name
- NCT03896945
- Testing
- AVP-786
- Where
- 72 sites in United States, Bulgaria and 2 more
- Volunteers
- 136 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Interactions of Fronto-Parietal High Frequency rTMS on Anterior Cingulate Cortex Activation in Schizophrenia
This will be a single site pilot study. 20 subjects with EPP (Early Phase Psychosis), defined as medical record documentation of the onset of clinically significant psychotic symptoms within the past 10 years, will be enrolled.
- Trial name
- rTMS-FPCC (NCT04309370)
- Testing
- 20 Hz rTMS
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Indiana University
Schizophrenia, Schizoaffective Disorder
Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder
This is a six week, double blind,placebo controlled study for patients with schizophrenia or schizoaffective disorder treated with an atypical antipsychotic for at least two months.
- Trial name
- NCT00373672
- Testing
- armodafinil (Nuvigil)
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Northwestern University
Schizophrenic Disorders
Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose
This pilot trial in Finland is designed to evaluate in a randomized fashion change of agitation in acute schizophrenic patients (Schizophrenia or Schizoaffective psychosis or Schizophreniformic psychosis)Diagnostic and…
- Trial name
- NCT00660595
- Testing
- Quetiapine, Risperidone
- Where
- 4 sites in Finland
- Volunteers
- 29 people
- Sponsor
- AstraZeneca
Schizophrenia
Safety and Efficacy of MP-214 in Patients With Schizophrenia
The objective of this study is to evaluate the efficacy, safety, and tolerability of MP-214 relative to placebo in patients with acute exacerbation of schizophrenia.
- Trial name
- NCT01625000
- Testing
- MP-214 3mg, MP-214 6mg, MP-214 9mg
- Where
- 3 sites in Japan, South Korea and 1 more
- Volunteers
- 512 people
- Sponsor
- Tanabe Pharma Corporation
Schizophrenia, Schizoaffective Disorder
Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics
Because ziprasidone has not been extensively studied and is not widely accepted in the severely mentally ill in State hospitals this study aims to demonstrate its effectiveness and relative lack of side effects.
- Trial name
- NCT00458211
- Testing
- ziprasidone
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Bronx Psychiatric Center
Schizophrenia
The Use of Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (The METS Study)
This study will test the usefulness of the medication metformin in treating people with schizophrenia or schizoaffective disorder who are overweight and also taking antipsychotic medications.
- Trial name
- METS (NCT00816907)
- Testing
- Metformin
- Where
- 16 sites in United States
- Volunteers
- 146 people
- Sponsor
- National Institute of Mental Health (NIMH)
Cognition in Schizophrenia
Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation
This research is being done because people with schizophrenia often have problems with thinking including learning, remembering, paying attention, and problem solving.
- Trial name
- NCT00628394
- Testing
- Atomoxetine
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- University of Texas Southwestern Medical Center
Schizophrenia
Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants
The purpose of this study is to characterize the safety and tolerability of TAK-063 when administered as multiple oral doses at escalating dose levels in participants with stable schizophrenia and in healthy Japanese participants.
- Trial name
- NCT01879722
- Testing
- TAK-063
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Takeda
Schizophrenia, Schizo Affective Disorder
D-serine Augmentation of Neuroplasticity
Schizophrenia is a major public health problem associated with cognitive deficits, such as short and long term memory, executive functioning, attention and speed of processing that are amongst the strongest predictors of impaired…
- Trial name
- NCT03711500
- Testing
- D-serine
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- New York State Psychiatric Institute
Schizophrenia
A Study of Flexibly Dosed Paliperidone Extended Release Tablets in Participants With Schizophrenia
The purpose of this study is to evaluate the effectiveness of paliperidone extended-release (ER; designed to slowly release a drug in the body over an extended period of time) tablets in participants with schizophrenia…
- Trial name
- NCT01541371
- Testing
- Paliperidone ER
- Volunteers
- 405 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Diet, Healthy, Psychotic Disorders
Weight Management Program for Patients With First Episode Psychosis
Severe mental illnesses (SMI), such as schizophrenia, are associated with increased morbidity and mortality in large part due to obesity and concomitant metabolic disorders.
- Trial name
- NCT05207982
- Testing
- Family Based weight management program
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- State University of New York at Buffalo
Schizophrenia, Psychosis
Prefrontal Cortical Engagement Through Non-Invasive Brain Stimulation in Schizophrenia
Cognitive impairments in schizophrenia are the most debilitating aspect of the illness and poorly treated by current medications.
- Trial name
- NCT02975973
- Testing
- transcranial direct current stimulation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Baylor College of Medicine
Childhood Schizophrenia, Psychotic Disorder
Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
The purpose of this study is to compare the effectiveness and side effects of the drugs clozapine and olanzapine in children and adolescents with schizophrenia and psychoses.
- Conditions
- Childhood Schizophrenia, Psychotic Disorder, Schizophrenia
- Trial name
- NCT00001656
- Testing
- Olanzapine, Clozapine
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Mental Health (NIMH)
Schizophrenia
Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)
This is a multi-site, open-label fixed-flexible dose long-term study of asenapine in participants with schizophrenia. Participants in this study consist of schizophrenia with residual subtype or receiving high dose/multiple…
- Trial name
- NCT01244828
- Testing
- Asenapine
- Volunteers
- 157 people
- Sponsor
- Organon and Co
Social Cognition, Social Anxiety
Oxytocin and Social Cognition in Schizophrenia
Objective: Social Cognition and Emotional Intelligence have been shown to be deficient in patients with schizophrenia and these are not remediated by antipsychotic medications or psychosocial interventions.
- Conditions
- Social Cognition, Social Anxiety, Emotional Intelligence
- Trial name
- NCT00884897
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Schizoaffective Disorder
Clinical Trial of Dipyridamole in Schizophrenia
This is a 6-week, randomized, double blind, parallel groups designed, olanzapine-controlled trial of oral dipyridamole in symptomatic patients with a (DSM IV) diagnosis of schizophrenia, schizoaffective or schizophreniform…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00349973
- Testing
- Dipyridamole, Olanzapine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia, Schizoaffective Disorder
Lifestyle Intervention for Young Adults With Serious Mental Illness
This is a four year project evaluating the effectiveness of a group-based lifestyle intervention (PeerFIT) supported by mobile health (mHealth) technology and social media compared to Basic Education in fitness and nutrition…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT02815813
- Testing
- PeerFIT, BEAT
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia
A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia
This study will evaluate the safety and tolerability of aripiprazole lauroxil (also known as ARISTADA, ALKS 9070).
- Trial name
- NCT02634320
- Testing
- Aripiprazole Lauroxil
- Where
- 18 sites in United States
- Volunteers
- 51 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
The objective of this study is to investigate the efficacy and safety of three different doses of aripiprazole (2 mg/day, 6-12 mg/day, 24-30 mg/day) orally administered over a period of 6 weeks in pediatric patients (aged 13-17…
- Trial name
- NCT01942161
- Testing
- Aripiprazole Low (2 mg/day), Aripiprazole Mid (6 - 12 mg/day), Aripiprazole High (24 - 30 mg/day)
- Where
- 8 sites in Japan
- Volunteers
- 106 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.